news/blog

English

keep_alive

_shopify_essential

_tracking_consent

unsen_shown_pages

localization

The domain name 'dcfmodeling.com' uses the commercial generic top-level domain (.com) and has no subdomain. Count 11 characters in 'dcfmodeling' with 3 vowels and 8 consonants. Segmentation suggests three words: dc, f, modeling. Median word length is 2 characters. The linguistic tilt is English for 'dc'. It also appears in Indonesian and Romanian contexts.

type

options[unavailable_products]

options[prefix]

form_type

utf8

_method

return_to

language_code

product

locale_code

email

customer[email]

customer[password]

customer[first_name]

customer[last_name]

html/f0/1e/f01e5dc3-6280-4a4f-96da-02de1cbe2799.html.gz

block-all-mixed-content; frame-ancestors 'none'; upgrade-insecure-requests;

sandbox allow-scripts allow-forms allow-modals allow-popups allow-downloads allow-top-navigation-by-user-activation

require-trusted-types-for 'script';report-uri /_/ContributorServingWebSwitchboardHttp/cspreport, script-src 'report-sample' 'nonce-T84CwngF1MW9LJIzyg2n1Q' 'unsafe-inline';object-src 'none';base-uri 'self';report-uri /_/ContributorServingWebSwitchboardHttp/cspreport;worker-src 'self', script-src 'unsafe-inline' 'unsafe-eval' blob: data: 'self' https://apis.google.com https://ssl.gstatic.com https://www.google.com https://www.googletagmanager.com https://www.gstatic.com https://www.google-analytics.com;report-uri /_/ContributorServingWebSwitchboardHttp/cspreport/allowlist

sandbox allow-scripts; report-to csp-reports

appId=cid-v1:24dd0b7c-7995-45d6-b3b6-925639dc2d30

script-src 'report-sample' 'nonce-_r4unrumWAkYkjacv_dulA' 'unsafe-inline';object-src 'none';base-uri 'self';report-uri /_/ContributorLoggingHttp/cspreport;worker-src 'self', script-src 'unsafe-inline' 'unsafe-eval' blob: data: 'self' https://apis.google.com https://ssl.gstatic.com https://www.google.com https://www.googletagmanager.com https://www.gstatic.com https://www.google-analytics.com;report-uri /_/ContributorLoggingHttp/cspreport/allowlist, require-trusted-types-for 'script';report-uri /_/ContributorLoggingHttp/cspreport

require-trusted-types-for 'script';report-uri /_/ContributorServingWebSwitchboardHttp/cspreport, script-src 'report-sample' 'nonce-Xzgjca2fIZxDYMPz3mxCkA' 'unsafe-inline';object-src 'none';base-uri 'self';report-uri /_/ContributorServingWebSwitchboardHttp/cspreport;worker-src 'self', script-src 'unsafe-inline' 'unsafe-eval' blob: data: 'self' https://apis.google.com https://ssl.gstatic.com https://www.google.com https://www.googletagmanager.com https://www.gstatic.com https://www.google-analytics.com;report-uri /_/ContributorServingWebSwitchboardHttp/cspreport/allowlist

frame-ancestors 'self'; report-uri /csp-report?source%5Baction%5D=web_pixel_javascript_response&source%5Bapp%5D=Shopify&source%5Bcontroller%5D=web_pixels&source%5Bsection%5D=services&source%5Buuid%5D=67a372f0-b7bb-48ea-80d9-3b0996bbde33-1759948422; report-to shopify-csp

require-trusted-types-for 'script';report-uri /_/ContributorServingWebSwitchboardHttp/cspreport, script-src 'report-sample' 'nonce-5xzcuIVsWGGRK-WO3SicPQ' 'unsafe-inline';object-src 'none';base-uri 'self';report-uri /_/ContributorServingWebSwitchboardHttp/cspreport;worker-src 'self', script-src 'unsafe-inline' 'unsafe-eval' blob: data: 'self' https://apis.google.com https://ssl.gstatic.com https://www.google.com https://www.googletagmanager.com https://www.gstatic.com https://www.google-analytics.com;report-uri /_/ContributorServingWebSwitchboardHttp/cspreport/allowlist

require-trusted-types-for 'script'; report-uri https://csp.withgoogle.com/csp/apps-themes

script-src 'report-sample' 'nonce-hqHHAYRiYxxjgnMnmDDo8Q' 'unsafe-inline';object-src 'none';base-uri 'self';report-uri /_/ContributorLoggingHttp/cspreport;worker-src 'self', script-src 'unsafe-inline' 'unsafe-eval' blob: data: 'self' https://apis.google.com https://ssl.gstatic.com https://www.google.com https://www.googletagmanager.com https://www.gstatic.com https://www.google-analytics.com;report-uri /_/ContributorLoggingHttp/cspreport/allowlist, require-trusted-types-for 'script';report-uri /_/ContributorLoggingHttp/cspreport

script-src 'report-sample' 'nonce-P1deew_RwuBRkmS9a_3_pQ' 'unsafe-inline';object-src 'none';base-uri 'self';report-uri /_/ContributorLoggingHttp/cspreport;worker-src 'self', script-src 'unsafe-inline' 'unsafe-eval' blob: data: 'self' https://apis.google.com https://ssl.gstatic.com https://www.google.com https://www.googletagmanager.com https://www.gstatic.com https://www.google-analytics.com;report-uri /_/ContributorLoggingHttp/cspreport/allowlist, require-trusted-types-for 'script';report-uri /_/ContributorLoggingHttp/cspreport

appId=cid-v1:7d42d046-dcef-4ece-9958-25d0ee39f9a0

__tcfapiLocator

__uspapiLocator

__gppLocator

googlefcInactive

googlefcLoaded

Breaking Down Vanda Pharmaceuticals Inc. (VNDA) Financial Health: Key Insights for Investors

Exploring Vanda Pharmaceuticals Inc. (VNDA) Investor Profile: Who’s Buying and Why?

Mission Statement, Vision, & Core Values of Vanda Pharmaceuticals Inc. (VNDA).

width=device-width, initial-scale=1, height=device-height, minimum-scale=1.0, maximum-scale=5.0

viewport

theme-color

ggDr0Xo80iGQZUjQgLmG6sOo368iLX1qoP56mfF3xY8

google-site-verification

msvalidate.01

Explore Vanda Pharmaceuticals history, mission, and ownership. Learn how it generates revenue and builds a strong portfolio in the industry.

description

Vanda Pharmaceuticals Inc. (VNDA): History, Ownership, Mission, How It Works & Makes Money,History,AI-Powered Discounted Cash Flow Editable Templates,dcfmodeling.com

keywords

author

AI-Powered Discounted Cash Flow Editable Templates

https://dcfmodeling.com/blogs/history/vnda-history-mission-ownership

Vanda Pharmaceuticals Inc. (VNDA): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biopharmaceutical company like Vanda Pharmaceuticals navigates the complex world of drug development and commercialization, especially with key products generating substantial revenue?
This company focuses on developing novel therapies for unmet medical needs, holding a unique position with approved treatments like HETLIOZ and Fanapt, which contributed significantly to its reported $215 million revenue in 2023.
Amidst ongoing clinical advancements and market dynamics, including recent takeover speculation, understanding their strategy becomes crucial.
Are you curious about how they build value and sustain growth in such a competitive landscape?
Vanda Pharmaceuticals Inc. (VNDA) History

Vanda Pharmaceuticals Inc.'s Founding Timeline
Understanding a company's origins often sheds light on its core strategy and culture. Vanda Pharmaceuticals began its journey with a specific focus.
Year established
2003
Original location
Washington, D.C., USA
Founding team members
Primarily founded by Mihael H. Polymeropoulos, MD, who has served as President and CEO since inception.
Initial capital/funding
The company initially raised capital through private placements and venture funding rounds before its Initial Public Offering (IPO). For instance, it completed its IPO in April 2006, raising approximately $67.5 million in net proceeds.

Vanda Pharmaceuticals Inc.'s Evolution Milestones
Tracking key developments shows how the company navigated the complex biopharmaceutical landscape.



Year
Key Event
Significance




2009
FDA Approval of Fanapt® (iloperidone)
Marked the company's transition to a commercial-stage entity, providing its first major revenue stream for treating schizophrenia in adults.


2014
FDA Approval of Hetlioz® (tasimelteon)
First FDA-approved treatment for Non-24-Hour Sleep-Wake Disorder, establishing Vanda in the circadian rhythm disorder market. This diversification was crucial.


2014
Acquisition of rights to Fanapt®
Gained full US and Canadian rights from Novartis, consolidating control over its initial commercial product.


2020
FDA Approval of Hetlioz® for Smith-Magenis Syndrome (SMS) nighttime sleep disturbances
Expanded the indication for Hetlioz®, targeting a rare genetic disorder and demonstrating pipeline potential.


2022
FDA Approval of Hetlioz® LQ (tasimelteon) oral suspension
Provided a liquid formulation option for Hetlioz®, potentially improving accessibility for certain patient populations.


2024
Ongoing Pipeline Development & Legal Battles
Continued focus on advancing clinical programs (e.g., tradipitant) while actively managing patent litigation and market exclusivity challenges, shaping future revenue potential. Understanding these dynamics is key when Breaking Down Vanda Pharmaceuticals Inc. (VNDA) Financial Health: Key Insights for Investors.




Vanda Pharmaceuticals Inc.'s Transformative Moments
Certain strategic decisions fundamentally altered the company's course.
Transition to Commercialization
Securing FDA approval for Fanapt® in 2009 was pivotal. It shifted Vanda from a purely developmental company to one with marketed products and revenue generation capabilities, a major leap for any biotech firm.
Focus on Circadian Rhythms
The development and subsequent FDA approval of Hetlioz® in 2014 wasn't just another product launch; it carved out a niche in the underserved market of circadian rhythm disorders, demonstrating Vanda's ability to identify and address unmet medical needs effectively.
Strategic Assertiveness
Vanda has shown a willingness to actively defend its intellectual property and pursue label expansions, such as with Hetlioz® for SMS. This strategic assertiveness in regulatory and legal arenas has become a defining characteristic, impacting market positioning and long-term growth prospects through 2024.
Vanda Pharmaceuticals Inc. (VNDA) Ownership Structure
Vanda Pharmaceuticals Inc. operates as a publicly traded entity, meaning its shares are available for purchase on the open market, leading to a diverse ownership base primarily dominated by large financial institutions.

Vanda Pharmaceuticals Inc. Current Status
As of the end of 2024, Vanda Pharmaceuticals Inc. is listed on the Nasdaq Global Select Market under the ticker symbol VNDA. Its status as a public company subjects it to regulatory oversight by the Securities and Exchange Commission (SEC), requiring regular financial disclosures and adherence to governance standards.

Vanda Pharmaceuticals Inc. Ownership Breakdown
The ownership structure reflects significant interest from institutional investors, which is common for established biopharmaceutical companies. Understanding who holds substantial stakes is crucial; you can delve deeper here: Exploring Vanda Pharmaceuticals Inc. (VNDA) Investor Profile: Who’s Buying and Why? Based on filings proximate to year-end 2024, the distribution is approximately as follows:



Shareholder Type
Ownership, %
Notes




Institutional Investors
~85%
Includes mutual funds, pension funds, hedge funds. Data based on latest available filings.


Retail & Other Public
~13%
Shares held by individual investors and smaller entities.


Insiders (Executives & Directors)
~2%
Reflects direct holdings by company leadership, subject to change based on transactions.




Vanda Pharmaceuticals Inc. Leadership
The strategic direction and day-to-day operations are managed by an executive team and overseen by a Board of Directors. Key leadership figures guiding the company as of late 2024 include:

Mihael H. Polymeropoulos, M.D. - President, Chief Executive Officer, and Chairman of the Board
Kevin T. Moran - Senior Vice President, Chief Financial Officer, and Treasurer
Timothy Williams - Senior Vice President, General Counsel, and Secretary

This team is responsible for executing the company's strategy, managing resources, and navigating the complex biopharmaceutical landscape.
Vanda Pharmaceuticals Inc. (VNDA) Mission and Values
Vanda Pharmaceuticals Inc. anchors its operations in a commitment to advancing medical science and improving patient outcomes through targeted therapies. The company's culture and strategic direction are guided by principles focused on innovation and addressing significant unmet medical needs.

Vanda Pharmaceuticals Inc. (VNDA) Core Purpose
Understanding the core purpose provides insight into the company's long-term goals and the principles guiding its research, development, and commercialization efforts. Investors often examine these foundational elements, as detailed in Exploring Vanda Pharmaceuticals Inc. (VNDA) Investor Profile: Who’s Buying and Why?, to gauge alignment with their own objectives.

Official mission statement
To develop and commercialize innovative therapies that address unmet medical needs and improve the lives of patients.

Vision statement
While not always formally stated as a distinct vision, Vanda's actions point towards a future where they are a leader in developing novel treatments for central nervous system disorders and other challenging conditions, continually expanding their therapeutic reach.

Company slogan
Vanda doesn't heavily promote a single, distinct public slogan, but their communications consistently emphasize innovation and patient-centric solutions.

Vanda Pharmaceuticals Inc. (VNDA) Core Values
The operational philosophy and ethical framework of the company are built upon several key values:

    
Innovation: Pursuing novel scientific approaches to create unique therapies.
    
Integrity: Conducting business with high ethical standards and transparency.
    
Patient Focus: Prioritizing the needs and well-being of patients in all endeavors.
    
Collaboration: Working effectively with partners, researchers, and the medical community.
    
Excellence: Striving for high performance and quality in research, development, and commercial activities.

Vanda Pharmaceuticals Inc. (VNDA) How It Works
Vanda Pharmaceuticals develops and commercializes innovative therapies targeting central nervous system disorders, focusing on unmet medical needs. The company generates revenue primarily through the sale of its approved pharmaceutical products, reinvesting capital into research and development for pipeline expansion.

Vanda Pharmaceuticals Inc.'s Product/Service Portfolio



Product/Service
Target Market
Key Features




HETLIOZ® (tasimelteon)
Patients with Non-24-Hour Sleep-Wake Disorder (Non-24); Patients with nighttime sleep disturbances associated with Smith-Magenis Syndrome (SMS)
First and only FDA-approved treatment for Non-24; Orphan drug designation providing market exclusivity for specific indications. Generated $23.9 million in net product sales in Q3 2024.


Fanapt® (iloperidone)
Adult patients with schizophrenia
Atypical antipsychotic medication; Available in oral tablet form. Achieved $18.6 million in net product sales during Q3 2024.


Pipeline Products
Various CNS and other disorders (e.g., bipolar disorder, atopic dermatitis, motion sickness)
Focus on novel mechanisms and addressing unmet needs through ongoing clinical trials. R&D investments were $10.9 million in Q3 2024.




Vanda Pharmaceuticals Inc.'s Operational Framework
Vanda's operational model centers on a cycle of research, development, regulatory approval, and commercialization. They identify potential drug candidates, often focusing on niche or underserved patient populations within the CNS space. Significant investment flows into clinical trials to demonstrate safety and efficacy – think rigorous Phase I, II, and III studies required by regulatory bodies like the FDA. For instance, R&D expenses reached $10.9 million in the third quarter of 2024 alone. Once approved, Vanda leverages its specialized sales and marketing teams (with SG&A expenses of $21.2 million in Q3 2024) to reach physicians and patients, driving adoption of therapies like HETLIOZ and Fanapt. Manufacturing is typically managed through partnerships with third-party contract manufacturing organizations (CMOs) to maintain flexibility and control costs, a common strategy I've seen succeed in specialized pharma.
Understanding who holds stakes in the company provides further context. Exploring Vanda Pharmaceuticals Inc. (VNDA) Investor Profile: Who’s Buying and Why? offers insights into the ownership structure.

Vanda Pharmaceuticals Inc.'s Strategic Advantages
Vanda possesses several key advantages in the competitive pharmaceutical landscape.


Focus on Niche Markets: By targeting conditions like Non-24 and SMS with HETLIOZ, Vanda operates in less crowded spaces, often benefiting from orphan drug status which grants periods of market exclusivity. This exclusivity is a powerful financial lever.

Established Commercial Infrastructure: The company has built dedicated sales forces and marketing strategies specifically for its products, particularly in the CNS therapeutic area. This allows for effective physician and patient outreach for HETLIOZ and Fanapt.

Clinical Development Expertise: Vanda has demonstrated capability in navigating the complex clinical trial and regulatory approval processes, bringing multiple products from development to market.

Strong Cash Position: With cash, cash equivalents and marketable securities reported at $381.3 million as of September 30, 2024, the company has substantial resources to fund ongoing R&D, potential acquisitions, and commercial activities. This financial stability is crucial for weathering the long development cycles typical in biotech.

Vanda Pharmaceuticals Inc. (VNDA) How It Makes Money
Vanda Pharmaceuticals generates revenue primarily through the sale of its commercialized pharmaceutical products. The company focuses on developing and commercializing therapies for central nervous system disorders.

Vanda Pharmaceuticals Inc.'s Revenue Breakdown



Revenue Stream
% of Total
Growth Trend




Hetlioz® (tasimelteon)
Approx. 55%

Decreasing


Fanapt® (iloperidone)
Approx. 45%

Increasing



Note: Percentages are estimates based on 2024 reported trends reflecting generic competition impact on Hetlioz sales and continued commercial efforts for Fanapt.

Vanda Pharmaceuticals Inc.'s Business Economics
The company operates within the specialty pharmaceutical sector, characterized by high research and development (R&D) costs necessary for drug discovery and clinical trials. Patent protection provides periods of market exclusivity, enabling premium pricing, but this is subject to expiry and potential generic competition, as seen with Hetlioz in 2024. Pricing is also heavily influenced by negotiations with payers and pharmacy benefit managers. Manufacturing costs (Cost of Goods Sold - COGS) are typically a smaller percentage of revenue for patented drugs but can increase relatively if pricing power diminishes. Significant Selling, General, and Administrative (SG&A) expenses are incurred for marketing, sales force deployment, and corporate overhead.

Key cost drivers include clinical trial expenses for pipeline candidates.
Sales and marketing investments are crucial for promoting Fanapt.
Legal costs associated with patent defense can also be substantial.


Vanda Pharmaceuticals Inc.'s Financial Performance
Based on trends observed through 2024, Vanda's overall revenue faced pressure primarily due to the introduction of generic competition for Hetlioz. Total net product sales showed a decline compared to prior years, with estimates placing full-year 2024 revenue likely below $200 million. While gross profit margins historically remained high, often above 90% due to the nature of specialty pharmaceuticals, the pressure on net revenue impacted overall profitability. Operating expenses, particularly R&D investment in pipeline assets like tradipitant and ongoing SG&A, remained significant factors. Consequently, operating income and net income experienced substantial declines in 2024 compared to previous profitable periods, potentially resulting in an operating loss for the fiscal year. For a deeper dive into the company's financial standing, consider Breaking Down Vanda Pharmaceuticals Inc. (VNDA) Financial Health: Key Insights for Investors. Evaluating these metrics is crucial for understanding the sustainability challenges and strategic pivots the company faced during this period.
Vanda Pharmaceuticals Inc. (VNDA) Market Position & Future Outlook
Vanda Pharmaceuticals navigates a specialized niche within the biopharmaceutical landscape, heavily reliant on its core products Hetlioz and Fanapt while pursuing pipeline expansion. Its future hinges on successful clinical development, particularly for Tradipitant, navigating patent cliffs, and managing regulatory pathways effectively amidst a dynamic competitive environment.

Competitive Landscape
The company competes in markets dominated by larger players but holds specific advantages in its targeted indications.



Company
Market Share, %
Key Advantage




Vanda Pharmaceuticals Inc.
Niche Specific
Strong position in Non-24-Hour Sleep-Wake Disorder (Hetlioz); Established presence in schizophrenia (Fanapt).


Jazz Pharmaceuticals
Significant Sleep Market Share
Dominant player in narcolepsy and related sleep disorders with products like Xywav/Xyrem.


Major Antipsychotic Players (e.g., J&J, Otsuka, Alkermes)
Large Schizophrenia Market Share
Extensive portfolios, broader labels, significant marketing resources, and established physician relationships.


Generic Manufacturers
Growing Pressure
Increasing competition as patents approach expiry, offering lower-cost alternatives.




Opportunities & Challenges
Strategic opportunities exist alongside significant potential hurdles for the company going forward.



Opportunities
Risks




Pipeline Advancement: Potential approval and launch of Tradipitant for gastroparesis could open a substantial new market.
Patent Expiration: Loss of exclusivity for key revenue drivers like Hetlioz and Fanapt poses a major threat from generic competition.


Label Expansion: Pursuing additional indications for existing drugs (e.g., Hetlioz for insomnia, Fanapt for bipolar disorder or pediatric use) could increase revenue streams.
Regulatory Setbacks: Unfavorable FDA decisions or delays regarding pipeline candidates or label expansions can significantly impact timelines and market potential. For instance, the Complete Response Letter for Hetlioz in insomnia in 2024 highlights this risk.


Market Growth: Growing awareness and diagnosis rates for targeted conditions like sleep disorders and CNS conditions present organic growth potential.
Clinical Trial Failures: Negative outcomes in late-stage clinical trials for pipeline candidates like Tradipitant would represent a major setback.


Strategic Partnerships/M&A: Potential collaborations or being an acquisition target could unlock value, although the company rejected a notable bid in 2024.
Reimbursement & Pricing Pressure: Increasing scrutiny from payors on drug pricing and formulary access can limit market uptake and profitability.




Industry Position
Vanda Pharmaceuticals operates as a focused biopharmaceutical entity concentrating on developing and commercializing therapies for central nervous system disorders. With total revenues around **$192.8 million** and R&D investments near **$60.8 million** reported for the fiscal year 2023, the company maintains a relatively small scale compared to industry giants. Its success has been built upon identifying and serving unmet needs in niche patient populations, as demonstrated by Hetlioz for Non-24 and Smith-Magenis Syndrome and Fanapt for schizophrenia. The company's strategy involves maximizing the value of its current portfolio while investing in its pipeline, aiming to bring novel treatments to market. Understanding the core principles guiding these efforts can be further explored through the Mission Statement, Vision, & Core Values of Vanda Pharmaceuticals Inc. (VNDA). Its industry standing is characterized by this specialized focus, contrasting with competitors boasting broader therapeutic portfolios and larger commercial infrastructures.
[right_ad_blog]

http://dcfmodeling.com/cdn/shop/articles/download_cee83ba3-6a00-4483-895c-89883a519e92.jpg?v=1730128265

https://dcfmodeling.com/cdn/shop/articles/download_cee83ba3-6a00-4483-895c-89883a519e92.jpg?v=1730128265

twitter:card

twitter:title

twitter:description

HRDZsM8YkDkG2R7WTYyePZXOjXbipVbzvRIn7eBSXZ0

shopify-digital-wallet

shopify-checkout-api-token

google-adsense-account

AlK2UR5SkAlj8jjdEc9p3F3xuFYlF6LYjAML3EOqw1g26eCwWPjdmecULvBH5MVPoqKYrOfPhYVL71xAXI1IBQoAAAB8eyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3NTgwNjcxOTksImlzU3ViZG9tYWluIjp0cnVlfQ==

Amm8/NmvvQfhwCib6I7ZsmUxiSCfOxWxHayJwyU1r3gRIItzr7bNQid6O8ZYaE1GSQTa69WwhPC9flq/oYkRBwsAAACCeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3NTgwNjcxOTksImlzU3ViZG9tYWluIjp0cnVlfQ==

A9nrunKdU5m96PSN1XsSGr3qOP0lvPFUB2AiAylCDlN5DTl17uDFkpQuHj1AFtgWLxpLaiBZuhrtb2WOu7ofHwEAAACKeyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9

A93bovR+QVXNx2/38qDbmeYYf1wdte9EO37K9eMq3r+541qo0byhYU899BhPB7Cv9QqD7wIbR1B6OAc9kEfYCA4AAACQeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9

A1S5fojrAunSDrFbD8OfGmFHdRFZymSM/1ss3G+NEttCLfHkXvlcF6LGLH8Mo5PakLO1sCASXU1/gQf6XGuTBgwAAACQeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXRhZ3NlcnZpY2VzLmNvbTo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9

HSTS header missing - vulnerable to protocol downgrade attacks

CSP header missing - vulnerable to XSS attacks

child-src 'none';object-src 'none';require-trusted-types-for 'script';script-src chrome://resources 'self';trusted-types;worker-src blob: 'self';frame-ancestors 'none';

child-src https:  chrome-untrusted://new-tab-page/ chrome-untrusted://ntp-microsoft-auth/;connect-src chrome://resources chrome://theme 'self';default-src 'self';font-src chrome://resources 'self';img-src chrome://resources chrome://theme chrome://image chrome://favicon2 chrome://app-icon chrome://extension-icon chrome://fileicon blob: data: 'self';object-src 'none';require-trusted-types-for 'script';script-src chrome://resources chrome://webui-test 'self';style-src chrome://resources chrome://theme 'self' 'unsafe-inline';trusted-types parse-html-subset sanitize-inner-html static-types webui-test-script webui-test-html polymer-html-literal polymer-template-event-attribute-policy lit-html-desktop;frame-ancestors 'none';

child-src 'none';object-src 'none';require-trusted-types-for 'script';script-src chrome://resources 'self';trusted-types;frame-ancestors 'none';

base-uri 'none';child-src https:;form-action https://ogs.google.com https://*.corp.google.com;object-src 'none';script-src 'self' 'unsafe-inline' https:;frame-ancestors chrome://new-tab-page/

DreamHost, LLC

DCFMODELING.COM


        {
            "@context": "https://schema.org",
            "@type": "Organization",
            "name": "dcfmodeling.com",
            "url": "https://dcfmodeling.com",
            "email": 


    {
        "@context": "http://schema.org",
        "@type": "Article",
        "about": "Ever wondered how a biopharmaceutical company like Vanda Pharmaceuticals navigates the complex world of dr


    {
        "@context": "http://schema.org",
        "@type": "BreadcrumbList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": 1,
      

window.performance && window.performance.mark && window.performance.mark('shopify.content_for_header.start');

var Shopify = Shopify || {};
Shopify.shop = "dcf-fm.myshopify.com";
Shopify.locale = "en";
Shopify.currency = {"active":"USD","rate":"1.0"};
Shopify.country = "US";
Shopify.theme = {"name":"Unsen 1.0 

!function(o){(o.Shopify=o.Shopify||{}).modules=!0}(window);

!function(o){function n(){var o=[];function n(){o.push(Array.prototype.slice.apply(arguments))}return n.q=o,n}var t=o.Shopify=o.Shopify||{};t.loadFeatures=n(),t.autoloadFeatures=n()}(window);

(function() {
  var isLoaded = false;
  function asyncLoad() {
    if (isLoaded) return;
    isLoaded = true;
    var urls = ["https:\/\/ecommplugins-scripts.trustpilot.com\/v2.1\/js\/header.min.js?se

var __st={"a":63051890837,"offset":7200,"reqid":"b12f80a9-11ad-4661-9399-bf9432d2cc16-1760067714","pageurl":"dcfmodeling.com\/blogs\/history\/vnda-history-mission-ownership?srsltid=AfmBOopKerOIc9Wt-l7

window.ShopifyPaypalV4VisibilityTracking = true;

!function(){'use strict';const t='contact',e='account',n='new_comment',o=[[t,t],['blogs',n],['comments',n],[t,'customer']],c=[[e,'customer_login'],[e,'guest_login'],[e,'recover_customer_password'],[e,

var Shopify=Shopify||{};Shopify.PaymentButton=Shopify.PaymentButton||{isStorefrontPortableWallets:!0,init:function(){window.Shopify.PaymentButton.init=function(){};var t=document.createElement("script


  function portableWalletsHideBuyerConsent(e){var t=document.getElementById("shopify-buyer-consent"),n=document.getElementById("shopify-subscription-policy-button");t&&n&&(t.classList.add("hidden"),t

document.addEventListener("DOMContentLoaded",(function(){function t(){return document.querySelector("shopify-accelerated-checkout-cart, shopify-accelerated-checkout")}if(t())Shopify.PaymentButton.init

window.performance && window.performance.mark && window.performance.mark('shopify.content_for_header.end');


  document.documentElement.className = document.documentElement.className.replace('no-js', 'js');function loadImageT4s(_this) { _this.classList.add('lazyloadt4sed')};(function() { document.documentEl

window.jdgmSettings={"pagination":5,"disable_web_reviews":false,"badge_no_review_text":"No reviews","badge_n_reviews_text":"{{ n }} review/reviews","badge_star_color":"#FFB400","hide_badge_preview_if_


!function(e){window.jdgm=window.jdgm||{},jdgm.CDN_HOST="https://cdn.judge.me/",
jdgm.docReady=function(d){(e.attachEvent?"complete"===e.readyState:"loading"!==e.readyState)?
setTimeout(d,0):e.addEven


    (function(c,l,a,r,i,t,y){
        c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)};
        t=l.createElement(r);t.async=1;t.src="https://www.clarity.ms/tag/"+i;
        y=l.getElements

(function() {function signalGooglefcPresent() {if (!window.frames['googlefcPresent']) {if (document.body) {const iframe = document.createElement('iframe'); iframe.style = 'width: 0; height: 0; border:


    /** Workaround for backward compatibility with old versions of localized themes */
    if (window.LangShopConfig && window.LangShopConfig.themeDynamics && window.LangShopConfig.themeDynamics.leng


!function(e){window.jdgm=window.jdgm||{},jdgm.CDN_HOST="https://cdnwidget.judge.me/",jdgm.API_HOST="https://api.judge.me/",jdgm.CDN_BASE_URL="https://cdn.shopify.com/extensions/0199c901-6518-7c40-a4b


  (function() {
    var jdgmThemeFixes = null;
    if (!jdgmThemeFixes) return;
    var thisThemeFix = jdgmThemeFixes[Shopify.theme.id];
    if (!thisThemeFix) return;

    if (thisThemeFix.html) {
 

(function(){if ("sendBeacon" in navigator && "performance" in window) {try {var session_token_from_headers = performance.getEntriesByType('navigation')[0].serverTiming.find(x => x.name == '_s').descri

(function e(e,d,r,n,o){if(void 0===o&&(o={}),!Boolean(null===(a=null===(i=window.Shopify)||void 0===i?void 0:i.analytics)||void 0===a?void 0:a.replayQueue)){var i,a;window.Shopify=window.Shopify||{};v


  window.ShopifyAnalytics = window.ShopifyAnalytics || {};
  window.ShopifyAnalytics.meta = window.ShopifyAnalytics.meta || {};
  window.ShopifyAnalytics.meta.currency = 'USD';
  var meta = {"page":{


  (function () {
    var customDocumentWrite = function(content) {
      var jquery = null;

      if (window.jQuery) {
        jquery = window.jQuery;
      } else if (window.Checkout && window.Chec

document.documentElement.style.setProperty('--topbar-height2', document.getElementById('shopify-section-top-bar').offsetHeight + 'px');


document.addEventListener('DOMContentLoaded', function () {
  class LocalizationForm extends HTMLElement {
    constructor() {
      super();
      this.elements = {
        input: this.querySelector

document.documentElement.style.setProperty('--header-height2', document.getElementById('shopify-section-header-inline').offsetHeight + 'px');

(adsbygoogle = window.adsbygoogle || []).push({});


document.addEventListener("DOMContentLoaded", function() {
  var checkboxes = document.querySelectorAll('input[name="product"]');
  var toggleButton = document.getElementById('toggle-templates-btn');


{
  "@context": "http://schema.org",
  "@type": "Article",
  "articleBody": "Ever wondered how a biopharmaceutical company like Vanda Pharmaceuticals navigates the complex world of drug development a

(adsbygoogle=window.adsbygoogle||[]).push({});

window.T4Srequest = {
    design_mode: false,
    page_type: 'article',
    path: "\/blogs\/history\/vnda-history-mission-ownership"
  };
  window.T4Sroutes = {
    root_url: '/',
    search_url: '/se

Shopify

HTTP/3

HSTS

Cloudflare Bot Management

Cloudflare

Vanda Pharmaceuticals Inc. (VNDA): history, ownership, mission, how it works & makes money – DCFmodeling.com

Microsoft

Google

⚠️ High Risk - https://dcfmodeling.com/blogs/history/vnda-history-mission-ownership?srsltid=AfmBOopKerOIc9Wt-l70RrSOip6-CvlP7KwjrVh9pmfpBQaH3E7_qIt8

Requests	IP Address	Location	AS Autonomous System
95	23.227.38.65	Ottawa, Ontario, Canada	AS13335CLOUDFLARENET
16	23.227.60.200	Canada	AS13335CLOUDFLARENET
6	142.250.186.110	United States	AS15169GOOGLE
5	142.250.185.99	United States	AS15169GOOGLE
4	52.242.103.142	Boydton, Virginia, United States	AS8075MICROSOFT-CORP-MSN-AS-BLOCK
3	34.120.110.54	Kansas City, Missouri, United States	AS396982GOOGLE-CLOUD-PLATFORM
2	142.250.186.138	United States	AS15169GOOGLE
2	18.172.112.105	United States	AS16509AMAZON-02
2	142.250.186.65	United States	AS15169GOOGLE
2	142.250.186.66	United States	AS15169GOOGLE
147	58	-	-

Security Scan Report: dcfmodeling.com

Summary

AI Security Verdict

Details

Screenshot

Page Load Overview

Language Analysis

Primary Language

Detection Details

Website Classification

Primary Category

All Detected Categories

Detected Features

Domain & IP Information

Detected Technologies5

Content Similarity HashesFor malware variant detection

TLSH (Trend Micro Locality Sensitive Hash)

ssdeep (Context Triggered Piecewise Hashing)

sdhash (Similarity Digest Hashing)

Image Hashes

Perceptual Hashes

Other Hashes

Scan History